CoChat

Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials

Open access
Jendle, Johan, Birkenfeld, Andreas L., Polonsky, William H., Silver, Robert, Uusinarkaus, Kari, Hansen, Thomas, Håkan‐Bloch, Jonas, Tadayon, Sayeh, Davies, Melanie J. · 2019 · Diabetes, Obesity and Metabolism
Cited by 19

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aim: To investigate treatment satisfaction with semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, versus placebo/active comparators in the SUSTAIN clinical trial programme. Methods: In SUSTAIN 2–5 and 7, the Diabetes Treatment Satisfaction Questionnaire was used to evaluate patient‐perceived treatment satisfaction, hyperglycaemia and hypoglycaemia. Post hoc subgroup analyses were conducted to explore the effects of gastrointestinal adverse events (GI AEs), weight loss (≥5%) or achieving glycaemic (HbA1c < 7%) targets on treatment satisfaction. Results: Overall treatment satisfaction increased from baseline to end of treatment with all treatments across trials. Improvements were significantly greater with semaglutide versus comparators/placebo in SUSTAIN 2–5 (all P < 0.05), and generally greater in patients who achieved versus did not achieve weight loss and glycaemic targets, often with greater improvements with semaglutide 1.0 mg versus comparator/placebo in both weight loss groups. In SUSTAIN 7, improvements in overall treatment satisfaction were generally similar between semaglutide and dulaglutide, irrespective of weight loss or glycaemic control. In SUSTAIN 7, changes in overall treatment satisfaction score were generally lower in patients with versus without GI AEs at week 16 (except dulaglutide 0.75 mg), but similar by week 40. Perceived hyperglycaemia was significantly reduced from baseline to end of treatment with semaglutide versus all comparators/placebo (all P < 0.05). No differences between treatments were observed for perceived hypoglycaemia. Conclusions: Semaglutide was associated with significantly greater (SUSTAIN 2–5) or similar (SUSTAIN 7) improvements in overall treatment satisfaction versus comparators/placebo. Improvements in overall treatment satisfaction were generally greater in patients achieving versus not achieving treatment targets. Clinicaltrials.gov : NCT01930188 (SUSTAIN 2), NCT01885208 (SUSTAIN 3), NCT02128932 (SUSTAIN 4), NCT02305381 (SUSTAIN 5) and NCT02648204 (SUSTAIN 7). EudraCT: 2012–004827‐19 (SUSTAIN 2), 2012–004826‐92 (SUSTAIN 3), 2013–004392‐12 (SUSTAIN 4), 2013–004502‐26 (SUSTAIN 5) and 2014–005375‐91 (SUSTAIN 7).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13816

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 19

Metadata

Authors
Jendle, J., Birkenfeld, A. L., Polonsky, W. H., Silver, R., Uusinarkaus, K., Hansen, T., Håkan‐Bloch, J., Tadayon, S., & Davies, M. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2019-07-12
Volume
21
Issue
10
Pages
2315-2326
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2952827750
Cited by
19
References
10
FWCI
1.55
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.